Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01726738 | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | completed | Phase 2 | 17 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00471887 | Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | completed | Phase 2 | 32 | Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Oct 26, 2020 |
| clinicaltrials |
| NCT01328535 | Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 25 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00525031 | Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients | completed | Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT02363283 | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2020 | clinicaltrials |
| NCT01512251 | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 8 | University of California, San FranciscoOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT00039325 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma | completed | Phase 1 / Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00300612 | Vaccine Treatment for Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01682213 | Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation | completed | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2020 | clinicaltrials |
| NCT01704287 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | completed | Phase 2 | 540 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 18, 2020 | clinicaltrials |
| NCT00005971 | Flavopiridol in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 9, 2020 | clinicaltrials |
| NCT02354690 | Vemurafenib and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 13 | Inge Marie SvaneOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT01363206 | Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma(GIPI) | completed | Phase 2 | 29 | Lynn E. Spitler, MDOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00062491 | Study of Karenitecin (BNP1350) to Treat Malignant Melanoma | completed | Phase 2 | 46 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01449279 | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT01266603 | High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT01413191 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2020 | clinicaltrials |
| NCT02583516 | Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma | completed | Phase 2 | 70 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01941927 | Trametinib With GSK2141795 in BRAF Wild-type Melanoma | completed | Phase 2 | 20 | Adil DaudOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT02537600 | Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis(CONVERCE) | completed | Phase 2 | 43 | Center Eugene MarquisOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02379195 | Peginterferon and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 12 | Inge Marie SvaneOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 24 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT02424916 | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study(MelSort) | completed | Phase 1 / Phase 2 | 7 | Nantes University HospitalOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02094872 | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | completed | Phase 2 | 49 | Yale UniversityOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT04180774 | Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer | completed | Phase 1 / Phase 2 | 80 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT00590824 | Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma | completed | Phase 2 | 23 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02014441 | Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec | completed | Phase 2 | 61 | AmgenINDUSTRY | 2 | Nov 20, 2019 | clinicaltrials |
| NCT00109863 | Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma | completed | Phase 2 | 14 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01196416 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01136967 | An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma | completed | Phase 2 | 182 | Eisai Inc.INDUSTRY | 4 | Nov 13, 2019 | clinicaltrials |
| NCT00314093 | RFT-5-dgA in Patients With Metastatic Melanoma | completed | Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01883323 | Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma | completed | Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01551459 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma(SUAVE) | completed | Phase 2 | 124 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT00254397 | Melanoma Vaccine With Peptides and Leuprolide | completed | Phase 2 | 98 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT03007823 | High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02768207 | A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 2 | Aug 28, 2019 | clinicaltrials |
| NCT01876212 | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | completed | Phase 2 | 15 | Walter J. StorkusOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01107665 | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | completed | Phase 2 | 60 | University of California, IrvineOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01636882 | CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)(CALMext) | completed | Phase 2 | 16 | ViralyticsINDUSTRY | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01227551 | A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )(CALM) | completed | Phase 2 | 57 | ViralyticsINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT02306850 | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma(NeoPembroMel) | completed | Phase 2 | 10 | St. Louis UniversityOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT00301067 | Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01258855 | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | May 10, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | completed | Phase 2 | 38 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01124734 | High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma | completed | Phase 2 | 17 | Milton S. Hershey Medical CenterOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 2 | Jan 29, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 23, 2020source: clinicaltrials